查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198723

血管闭合装置 (VCD) 市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Vascular Closure Device (VCD) Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

血管闭合装置 (VCD) 市场预计在预测期内 (2022-2027) 的复合年增长率为 6.82%。

在 COVID-19 大流行期间，非紧急手术的减少影响了市场的增长。 根据 2021 年 12 月在 JAMA Network Open 上发表的文章“美国外科手术的趋势和医疗保健系统对在 COVID-19 大流行期间限制选择性外科手术的政策的反应”，大流行正在影响医疗护理，包括外科护理。他说影响了方方面面。 该论文分析了美国 2020 年 11 月至 2021 年 7 月的手术数据，指出 2020 年 3 月至 4 月的初始停工期与手术量的减少有关。 限制解除后，手术率已恢復到 2019 年的水平。 在 COVID-19 大流行期间，手术数量的这种下降阻碍了市场增长。

导管相关手术的增加、对微创解决方案的需求不断增长以及 VCD 的易用性等因素，再加上心血管疾病负担的增加，正在推动市场的增长。 越来越多的患者选择微创球囊成形术，因为微创手术具有手术痛苦小、损伤小、疤痕小、住院时间短、准确性高、恢復快等几个优点。 心血管疾病及其死亡率日益增加的负担创造了对治疗设备的需求，从而推动了市场增长。 例如，世界卫生组织 (WHO) 的一篇题为“心血管疾病”的文章。 2021 年 6 月更新的“关键事实”报告称，心血管疾病 (CVD) 是全球死亡的主要原因。

此外，市场增长还受到新产品发布的推动。 例如，2021 年 9 月，Haemonetics Corporation 的 VASCADE MVP 静脉血管闭合系统获得了美国食品药品监督管理局的批准。 因此，各种市场参与者产品的监管批准数量正在推动市场增长。 然而，产品的高成本和与 VCD 相关的复杂性可能会阻碍预测期内的市场增长。

血管闭合装置 (VCD) 市场趋势

预计在预测期内股骨通路部分将出现显着增长

用于股动脉通路的血管闭合装置是介入心脏病专家和其他程序专家在导管插入部位实现止血的有力工具。 证明股动脉血管闭合装置好处的研究推动了这一细分市场的增长。 例如，“Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in everyday practice study, CLOSE-UP III”发表于 2022 年 2 月 BMC Cardiovascular Disorders 试验”市场上两种血管闭合装置的安全性和有效性。 结果，两者都得出结论，严重血管不良事件的发生很少见。 股骨通路血管闭合装置的这些优点促进了它们的使用，从而促进了细分市场的增长。

此外，市场参与者之间在不同地区的设备营销和商业化合作正在推动该细分市场的增长。 例如，2022 年 5 月，医疗技术提供商 Teleflex Incorporated 获得了加拿大卫生部对 MANTA 血管闭合装置的批准，这是第一款专为大直径股动脉通路闭合而设计的商用生物力学血管闭合装置。 MANTA 装置适用于在血管内导管插入术中使用 10-20F 装置或护套（12-25F 外径）后，股动脉通路部位闭合，止血时间缩短。

在此背景下，市场有望在预测期内显着增长。

北美占据了市场的主要份额，预计在预测期内也会如此。

不断增长的医疗基础设施、不断增加的心血管疾病负担以及导管相关手术的增加，以及该国对微创解决方案不断增长的需求正在推动该地区的市场增长。我来了。 根据疾病控制与预防中心 (CDC) 题为“心脏病事实”的文章，该文章于 2022 年 2 月更新，心脏病是美国的头号死因。 另据报导，美国每年约有65.9万人死于心脏病。 如此高的疾病负担导致了对血管闭合装置的需求，并正在推动该地区的市场增长。

此外，美国食品药品监督管理局和加拿大卫生部等监管机构的批准也在推动市场增长。 例如，2021年4月，EnsiteVascular获得美国食品药品监督管理局（FDA）第二次批准，其SiteSeal SV（小血管）VCD加压装置可在经支气管血管内治疗后实现肱动脉止血，并获得上市许可。 SiteSeal SV 是一种新型闭塞装置，专为闭塞小动脉（尤其是肱动脉、桡动脉和足动脉）而设计。 模拟外部压缩，但删除相关变量，什么也不留下。

2021 年 10 月，Haemonetics 还获得了美国食品和药物管理局的批准，可以在使用该公司的 Vascade MVP 静脉血管闭合系统进行房颤消融后当天出院。 Vascade MVP 是一种血管闭合系统，适用于需要在多个通路部位进行静脉闭合的手术。

因此，由于上述因素，预计在预测期内，北美地区的血管闭合装置市场将出现显着增长。

血管闭合装置 (VCD) 市场竞争对手分析

由于竞争对手之间的激烈竞争，预计该市场将出现利润丰厚的增长，从而导致该行业产生高收入。 这个市场的参与者正致力于开发新的 VCD 并扩展他们的产品组合。 通过与中小型公司的收购和合作伙伴关係增加影响力也将推动该行业的增长。 市场上的主要参与者是雅培实验室、Cardinal Health Inc.、Biotronik SE &Co.KG、Cardinal Health Inc.、CardivaMedical Inc. 和 Terumo Corporation。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 增加导管相关手术
    • 对微创解决方案的需求增加
    • VCD 的可用性
  • 市场製约因素
    • 产品成本高
    • 与 VCD 相关的并发症
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（按价值计算的市场规模：百万美元）

  • 产品类型
    • 主动式加速度计
      • 剪辑设备
      • 使用缝线的装置
      • 可插拔
    • 被动逼近器
      • 止血垫/贴片
      • 压缩机
  • 如何访问
    • 股骨入路
    • 径向访问
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Abbott Laboratories
    • Advanced Vascular Dynamics
    • B. Braun Melsungen AG
    • Biotronik SE & Co. KG
    • Becton, Dickinson and Company（C.R. Bard Inc.）
    • Cardinal Health Inc.
    • Cardiva Medical Inc.
    • Vivasure Medical Ltd
    • Medtronic PLC
    • Terumo Corporation

第7章 市场机会今后动向

简介目录
Product Code: 66042

The vascular closure device (VCD) market is anticipated to exhibit a CAGR of 6.82 % over the forecast period (2022-2027).

During the COVID-19 pandemic, there was a reduction in the non-emergency surgical procedure, which impacted the growth of the market. According to an article titled "Trends in US Surgical Procedures and Health Care System Response to Policies Curtailing Elective Surgical Operations During the COVID-19 Pandemic" published in the journal of JAMA Network Open in December 2021, the pandemic had affected every aspect of medical care, including the surgical treatments. The article analyzed the surgical data in the United States from November 2020 through July 2021 and indicated that the initial shutdown period in March 2020 through April 2020, was associated with a decrease in surgical procedure volumes. After the restrictions were lifted, the rate of surgical procedures rebounded to 2019 levels. Such reductions in the surgical volumes hindered the growth of the market during the COVID-19 pandemic.

Factors such as an increase in catheterization-related procedures, a rise in demand for minimally invasive solutions, and ease of usage of VCDs, coupled with the growing burden of cardiovascular diseases, are driving the growth of the market. The several advantages of minimally invasive surgeries, such as reduced surgical pain, injury, scarring, hospital stay, higher accuracy, and speedy recovery time, are encouraging an increasing number of patients to opt for minimally invasive balloon angioplasty surgeries. The growing burden of cardiovascular disease and deaths due to it generates the need for devices for the treatment and hence drives the market's growth. For instance, the World Health Organization article titled 'Cardiovascular Diseases: Key Facts' updated in June 2021, reported that cardiovascular diseases (CVDs) are the leading cause of death globally.

Additionally, the market growth is also propelled by the launch of new products. For instance, in September 2021, Haemonetics Corporation received the United States Food and Drug Administration's approval for VASCADE MVP Venous Vascular Closure System. Thus, the number of approvals by the regulatory authority for the products by different market players is boosting the growth of the market. However, the high cost of products and complications associated with VCDs may hinder the growth of the market over the forecast period.

Vascular Closure Device (VCD) Market Trends

Femoral Access Segment is Expected to Show Significant Growth Over the Forecast Period

Femoral vascular closure devices are powerful tools for interventional cardiologists and other proceduralists to achieve hemostasis at the catheterization entry site. The market segment growth is boosted by the research studies demonstrating the benefits of femoral vascular closure devices. For instance, an article titled "Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in everyday practice study, CLOSE-UP III trial" published in the journal of BMC Cardiovascular Disorders in February 2022 compared the safety and efficacy of two vascular closure devices available in the market. The study concluded that the occurrence of a major adverse vascular event was rare in both cases. Such benefits of the femoral access vascular closure devices promote their usage, hence driving the growth of the market segment.

Additionally, the collaboration among the market players for the marketing and commercialization of devices in different regions is driving the growth of the market segment. For Instance, in May 2022, Teleflex Incorporated, a medical technologies provider, received Health Canada approval for the MANTA Vascular Closure Device, the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure. MANTA Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.

Thus, owing to the abovementioned factors, the market segment is expected to grow significantly over the forecast period.

North America Holds Major Share in the Market and is Expected to do the Same Over the Forecast Period.

The well-established healthcare infrastructure, the growing burden of cardiovascular diseases, coupled with an increase in catheterization-related procedures, and the rise in demand for minimally invasive solutions in the country are driving the growth of the market in the region. According to the Center for Disease Control and Prevention (CDC) article titled 'Heart Diseases Facts' updated in February 2022, heart disease is the leading cause of death in the United States. It also reported that about 659,000 people in the United States die from heart disease each year. Such a high burden of the disease generates the need for vascular closure devices and drives the growth of the market in the region.

Additionally, the market growth is also boosted by approval from regulatory authorities such as the United States Food and Drug Administration and Health Canada. For instance, in April 2021, EnsiteVascular received its second United States Food and Drug Administration (FDA) market clearance for the company's SiteSeal SV (small vessel) VCD compression device to achieve hemostasis of the brachial artery after a transbronchial endovascular procedure. SiteSeal SV is a new closure device designed for the closure of small arterial vessels, specifically brachial, radial and pedal. It simulates external compression, but removes the associated variables, leaving nothing behind.

Also, in October 2021, Haemonetics received approval from the United States Food and Drug Administration for same-day discharge after atrial fibrillation ablation using its Vascade MVP venous vascular closure system. Vascade MVP is a vascular closure system that is designed for procedures that require multiple access site venous closures.

Thus, owing to the abovementioned factors, the vascular closure device market is expected to project significant growth in the North American region over the forecast period.

Vascular Closure Device (VCD) Market Competitor Analysis

This market is expected to witness lucrative growth due to a high level of competitive rivalry, which translates to high revenue generation in this sector. The prominent players in this market are involved in developing novel VCDs and, in turn, broadening their product portfolios. Acquisition and collaboration with small companies to enhance presence are also expected to propel growth in this vertical. The major players in the market are Abbott Laboratories, Cardinal Health Inc., Biotronik SE & Co. KG, Cardinal Health Inc., CardivaMedical Inc., and Terumo Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Catheterization-related Procedures
    • 4.2.2 Increase in Demand for Minimally Invasive Solutions
    • 4.2.3 Ease of Use of VCDs
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Products
    • 4.3.2 Complications Associated with VCDs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product Type
    • 5.1.1 Active Approximators
      • 5.1.1.1 Clip-based Devices
      • 5.1.1.2 Suture-based Devices
      • 5.1.1.3 Plug-based Devices
    • 5.1.2 Passive Approximators
      • 5.1.2.1 Hemostatic Pads and Patches
      • 5.1.2.2 Compression Devices
  • 5.2 Mode of Access
    • 5.2.1 Femoral Access
    • 5.2.2 Radial Access
  • 5.3 End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centres
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Advanced Vascular Dynamics
    • 6.1.3 B. Braun Melsungen AG
    • 6.1.4 Biotronik SE & Co. KG
    • 6.1.5 Becton, Dickinson and Company (C.R. Bard Inc.)
    • 6.1.6 Cardinal Health Inc.
    • 6.1.7 Cardiva Medical Inc.
    • 6.1.8 Vivasure Medical Ltd
    • 6.1.9 Medtronic PLC
    • 6.1.10 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS